A pivot from synaptic monoamine processes to further downstream processes: The impact of ketamine research.
Currently only one-third of patients treated for depression enjoy complete remission of their negative symptoms. This paper explores ketamine research as it applies to understanding and treating mood illnesses. Ketamine's rapid antidepressant effect implicates downstream signal transduction involving the spontaneous transmissions associated with ketamine's action at the NMDA receptor. Better understanding of brain neuropathophysiology offers hope for symptom relief to those living with affective illness refractory to currently available medical management.